急变期慢性髓性白血病的治疗:一种罕见且具有挑战性的疾病
本文综述急变期慢性髓性白血病(BP-CML)的治疗。尽管BCR-ABL特异性酪氨酸激酶抑制剂(TKI)在慢性期(CP)CML中成功,BP-CML患者中位生存期仍不足一年。综述评估单用TKI、联合强化化疗、异基因造血干细胞移植、新药及临床试验的数据,并讨论诊断BP和评估疗效的方法及预后因素。
要点
- BP-CML患者中位生存期不足一年,仍是CML管理中未满足的临床需求。
- 基因组不稳定导致突变获得,驱动白血病祖细胞自我更新,造成分化阻滞和预后不良的急性白血病。
- BP-CML罕见且异质,难以设计和招募前瞻性临床试验,亟需治疗进展。
核心结论
- BP-CML患者继续面临 dismal 结局,中位生存期不足一年,是CML管理中关键的未满足临床需求。
- BP-CML的罕见性和异质性导致难以设计和招募前瞻性临床试验,亟需治疗进展。
研究设计与样本
- 本文为综述,探讨BP-CML的治疗,评估单用TKI、联合强化化疗、异基因造血干细胞移植、新药及临床试验的数据。
- 综述还讨论诊断BP和评估疗效的最适当方法及预测结局的因素。
主要发现
- 基因组不稳定导致突变获得,驱动白血病祖细胞发展自我更新特性,导致分化阻滞和预后不良的急性白血病,可为髓系、淋系或双表型。
- BP-CML患者中位生存期不足一年。
局限性
- BP-CML的罕见性和异质性导致难以设计和招募前瞻性临床试验。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the success of BCR-ABL-specific tyrosine kinase inhibitors (TKIs) such as imatinib in chronic phase (CP) chronic myeloid leukaemia (CML), patients with blast phase (BP)-CML continue to have a dismal outcome with median survival of less than one year from diagnosis. Thus BP-CML remains a critical unmet clinical need in the management of CML. Our understanding of the biology of BP-CML continues to grow; genomic instability leads to acquisition of mutations which drive leukaemic progenitor cells to develop self-renewal properties, resulting in differentiation block and a poor-prognosis acute leukaemia which may be myeloid, lymphoid or bi-phenotypic. Similar advances in therapy are urgently needed to improve patient outcomes; however, this is challenging given the rarity and heterogeneity of BP-CML, leading to difficulty in designing and recruiting to prospective clinical trials. This review will explore the treatment of BP-CML, evaluating the data for TKI therapy alone, combinations with intensive chemotherapy, the role of allogeneic haemopoietic stem cell transplantation, the use of novel agents and clinical trials, as well as discussing the most appropriate methods for diagnosing BP and assessing response to therapy, and factors predicting outcome.
引用
- Copland M. Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity. Br J Haematol. 2022. PMID: 35866251. doi:10.1111/bjh.18370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。